The purpose of the study is to find out if giving allopurinol sodium shortly after birth and around the time of heart surgery can help protect the brain from injury. The study will involve monitoring the newborns before and after surgery using various methods, including MRI scans to check for brain injury, and other tests to assess brain and heart function. The study will also look at the overall development of the children as they grow, including their movement and cognitive skills at different ages.

Throughout the study, researchers will gather information on how well allopurinol sodium works and its cost-effectiveness. The study aims to provide valuable insights into whether this treatment can improve outcomes for newborns with critical congenital heart disease undergoing surgery.

Participants in the study will receive either Esketamine Hydrochloride or Sodium Chloride through an infusion, which is a method of delivering medication directly into the bloodstream. The treatment will last for a maximum of 14 days. During this time, researchers will monitor the patients to see how often these brain activities occur and to check for any side effects or reactions to the treatment. The study aims to understand if Esketamine Hydrochloride can help patients whose brain activities continue despite other treatments.

After the treatment period, the study will continue to follow up with participants to assess their recovery and overall health outcomes. This will include evaluating their functional abilities six months after the treatment using standard scales like the modified Rankin Scale and the Glasgow Outcome Scale-Extended. The results of this study could provide valuable insights into new treatment options for individuals with severe brain injuries.

The study will involve administering the treatment through an intravenous infusion, which means the solution is given directly into a vein. Another solution, Plasmalyte A Viaflo, which contains a mix of electrolytes like magnesium chloride hexahydrate, potassium chloride, sodium chloride, sodium acetate trihydrate, and sodium gluconate, may also be used. The purpose of the study is to see if these treatments can help improve outcomes for patients by decreasing the extent of brain injury after a cardiac arrest.

Participants in the study will receive the treatment for a short period, and their progress will be monitored over time. The study will look at various outcomes, such as the level of certain proteins in the blood that indicate brain injury, the patient’s recovery in terms of brain function, and their overall health status during their stay in the hospital. The goal is to gather information that could lead to better treatments for people who have suffered a cardiac arrest and are in a coma.

Participants in the study will receive either the apomorphine hydrochloride treatment or a placebo, which is a substance with no active medication. The study will last for a period of up to 30 days. During this time, researchers will monitor changes in the patients’ conditions using various methods, including the Coma Recovery Scale, which helps assess the level of consciousness. Other assessments may include changes in brain activity measured by EEG (a test that detects electrical activity in the brain), and imaging techniques like MRI and PET scans, which provide detailed pictures of the brain.

The study aims to determine if apomorphine hydrochloride can improve the condition of patients with severe brain injuries by enhancing their level of consciousness. Researchers will also look at other factors such as sleep patterns and body temperature changes to gain a comprehensive understanding of the treatment’s effects. The trial is expected to continue until 2028, providing valuable insights into the potential benefits of this treatment for individuals with severe brain injuries.

The purpose of the study is to see if a protein called tau is increased in the brains of people with these conditions compared to those without brain injuries. The study aims to find out where in the brain this increase happens. Participants will undergo a PET scan, which is a type of imaging test that helps doctors see how the brain is functioning. The tracer, [18F]RO6958948, helps to make the tau protein visible during the scan.

During the study, participants will receive an injection of the tracer and then have a PET scan. This process helps researchers gather information about the presence and location of tau in the brain. The study is designed to improve understanding of brain injuries and concussions, which may lead to better treatments in the future. Participants will be monitored throughout the study to ensure their safety and well-being.

The purpose of the study is to evaluate how effective ketamine is in improving consciousness in patients who have experienced a coma. The trial will compare the effects of ketamine to a placebo, which is a substance with no active medication. Participants will receive the treatment through an intravenous infusion, which is a method of delivering fluids directly into a vein. The study will monitor any new signs of consciousness, such as the ability to respond to commands, and will also assess changes in brain activity.

Throughout the study, researchers will use various methods to measure brain activity and other physical responses. These methods include fMRI (functional magnetic resonance imaging), which looks at brain activity by detecting changes in blood flow, and EEG (electroencephalogram), which records electrical activity in the brain. The study aims to understand how ketamine affects brain complexity and connectivity, which are important for consciousness. The trial is expected to continue until 2027, providing valuable insights into the potential benefits of ketamine for patients with disorders of consciousness.